These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12727078)

  • 1. In vitro pharmacodynamic properties of a fluoroquinolone pharmaceutical derivative: hydrochloride of ciprofloxacin-aluminium complex.
    Alovero FL; Olivera ME; Manzo RH
    Int J Antimicrob Agents; 2003 May; 21(5):446-51. PubMed ID: 12727078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Shevchenko AA; Cornaglia G
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1281-7. PubMed ID: 9174184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
    Thorburn CE; Edwards DI
    J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin.
    López-Rojas R; Sánchez-Céspedes J; Docobo-Pérez F; Domínguez-Herrera J; Vila J; Pachón J
    Int J Antimicrob Agents; 2011 Oct; 38(4):355-9. PubMed ID: 21820876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
    Smirnova LB; Sokolova VI
    Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
    Aeschlimann JR; Kaatz GW; Rybak MJ
    J Antimicrob Chemother; 1999 Sep; 44(3):343-9. PubMed ID: 10511401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of ciprofloxacin, fleroxacin and lomefloxacin in vivo and in vitro.
    Fuentes F; Martín MM; Izquierdo J; Gomez-Lus ML; Prieto J
    Chemotherapy; 1996; 42(5):354-62. PubMed ID: 8874975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
    Pendland SL; Neuhauser MM; Garey KW; Prause JL; Jung R
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):59-61. PubMed ID: 12376032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.
    Gebru E; Lee JS; Chang ZQ; Hwang MH; Cheng H; Park SC
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3024-9. PubMed ID: 19398644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
    Fuchs PC; Barry AL; Brown SD
    J Chemother; 1997 Dec; 9(6):391-3. PubMed ID: 9491837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?
    Czock D; Rasche FM
    Eur J Med Res; 2005 Apr; 10(4):145-8. PubMed ID: 15946909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone pharmacodynamics and efficacy.
    Doern GV; Tillotson GS
    Chest; 2001 Jul; 120(1):319-20. PubMed ID: 11451862
    [No Abstract]   [Full Text] [Related]  

  • 18. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
    Cooper MA; Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Sep; 28(3):399-405. PubMed ID: 1660046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2002 Jun; 10(2):100-6. PubMed ID: 12702887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin conjugated to diphenyltin(IV): a novel formulation with enhanced antimicrobial activity.
    Chrysouli MP; Banti CN; Kourkoumelis N; Moushi EE; Tasiopoulos AJ; Douvalis A; Papachristodoulou C; Hatzidimitriou AG; Bakas T; Hadjikakou SK
    Dalton Trans; 2020 Aug; 49(33):11522-11535. PubMed ID: 32656556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.